The recalling of thousands of COLLEAGUE and SYNDEO PCA infusion pumps by the FDA has cost Baxter over $170 million from 2005 - 2006.
Baxter pays it executives generously with money that could be invested towards increasing the firm's growth.
The infusion pump woes could have a broader impact on the Baxter brand name and impact sales in other segments if the problem is not resolved soon.